Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

已收盘 08-14 16:00:00 EDT

57.24

+1.37

+2.45%

盘后56.18

-1.06-1.85%

19:34 EDT

最高57.24	最低55.16	成交量135.37万
今开55.16	昨收55.87	日振幅3.72%
总市值95.12亿	流通市值92.68亿	总股本1.66亿
成交额7,655万	换手率0.84%	流通股本1.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":57.24,"timestamp":1786737600000,"preClose":55.87,"halted":0,"volume":1353737,"hourTrading":{"tag":"盘后","latestPrice":56.18,"preClose":57.24,"latestTime":"19:34 EDT","volume":50641,"amount":2888062.1686,"timestamp":1786750441327,"change":-1.06,"changeRate":-0.018519,"amplitude":0.018519},"delay":0,"changeRate":0.02452120995167361,"floatShares":161921007,"shares":166184322,"eps":-3.48,"marketStatus":"已收盘","change":1.37,"latestTime":"08-14 16:00:00 EDT","open":55.16,"high":57.24,"low":55.16,"amount":76552778.203825,"amplitude":0.037229,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.48,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":55.87,"preHourTrading":{"tag":"盘前","latestPrice":55.27,"preClose":55.87,"latestTime":"09:28 EDT","volume":1031,"amount":57456.86706,"timestamp":1786714096086,"change":-0.6,"changeRate":-0.010739,"amplitude":0.022731},"postHourTrading":{"tag":"盘后","latestPrice":56.18,"preClose":57.24,"latestTime":"19:34 EDT","volume":50641,"amount":2888062.1686,"timestamp":1786750441327,"change":-1.06,"changeRate":-0.018519,"amplitude":0.018519},"volumeRatio":0.674412,"impliedVol":0.4775,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"1136465309","title":"异动解读｜Ionis Pharmaceuticals盘中上涨5.39%，报56.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136465309","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136465309?lang=zh_cn&edition=full","pubTime":"2026-07-23 21:57","pubTimestamp":1784815031,"startTime":"0","endTime":"0","summary":"7月23日，Ionis Pharmaceuticals盘中上涨5.39%，报56.92美元/股，成交额2821.87万美元。Ionis Pharmaceuticals所在的生物科技行业中，个股中，艾伯维公司涨0.6%，Argenx SE涨3.77%，再生元制药公司跌1.98%，吉利德科学跌1.98%，安进跌1.22%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116842451","title":"异动解读｜Ionis Pharmaceuticals盘中下跌5.16%，财报前机构偏空叠加心血管管线挫折余波","url":"https://stock-news.laohu8.com/highlight/detail?id=1116842451","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116842451?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:37","pubTimestamp":1784727454,"startTime":"0","endTime":"0","summary":"7月22日，Ionis Pharmaceuticals盘中下跌5.16%，报51.395美元/股，成交额3660.52万美元。消息面上，公司与阿斯利康联合开发的Eplontersen心脏转归III期试验于7月9日公布结果，在第140周未达主要终点，股价此前已单日暴跌超20%。随后RBC将目标价从100美元下调至85美元，TD Cowen从108美元下调至94美元。心血管核心管线受挫、目标价下修及财报不确定性三重因素叠加，短期内持续压制股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119990036","title":"异动解读｜Ionis Pharmaceuticals盘前下跌6.35%，财报前机构偏空叠加管线挫折余波","url":"https://stock-news.laohu8.com/highlight/detail?id=1119990036","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119990036?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:33","pubTimestamp":1784720018,"startTime":"0","endTime":"0","summary":"7月22日，Ionis Pharmaceuticals盘前下跌6.35%，报50.0美元/股，成交额7.72万美元。此前7月9日，公司与阿斯利康联合开发的Eplontersen心脏转归III期试验未达主要终点，股价曾单日暴跌超20%。随后RBC将目标价从100美元下调至85美元，TD Cowen从108美元下调至94美元，市场情绪持续承压。尽管公司在Diranersen及Zilganersen等管线取得积极进展，但短期内核心心血管管线受挫及财报季不确定性仍主导股价走势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163634673","title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收或小幅回落，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1163634673","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163634673?lang=zh_cn&edition=full","pubTime":"2026-07-22 12:19","pubTimestamp":1784693967,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc将于2026年07月29日发布最新季度财报，市场关注商业化放量与研发推进节奏对利润率的影响。Ionis Pharmaceuticals, Inc的收入结构对合作与里程碑事件高度敏感，在高基数季度后，若本季度缺乏同等量级的合作里程碑，营收回落压力将上升。近期分析师对Ionis Pharmaceuticals, Inc的短期业绩持偏谨慎态度，看空比例更高，核心依据在于合作里程碑的不确定性与费用刚性的组合使得本季度营收与利润率面临回落风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收或小幅回落，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173298853","title":"Biogen公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益及强劲Tau蛋白降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1173298853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173298853?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:24","pubTimestamp":1784035453,"startTime":"0","endTime":"0","summary":"在阿尔茨海默病协会国际会议（AAIC）上，Ionis Pharmaceuticals 的合作伙伴百健（Biogen）公布了Celia二期研究数据。结果显示，在早期阿尔茨海默病患者中，候选药物Diranersen展现出具有临床意义的积极结果，并实现了Tau蛋白水平的强劲降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138442146","title":"“木头姐”再度调整持仓，加码Meta、减持AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=1138442146","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138442146?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:38","pubTimestamp":1783694306,"startTime":"0","endTime":"0","summary":"方舟投资创始人兼首席投资官Cathie Wood周四继续调整投资组合，大举加仓 $Meta Platforms, Inc.$，同时进一步减持芯片巨头 $美国超微公司$。这也是Meta将于7月29日公布第二季度业绩前的重要布局。此外，Meta近期持续加码AI业务，不仅推出首个付费AI模型，还宣布自研AI芯片将于9月进入量产阶段。与此同时，ARK继续减持AMD，合计卖出10774股，套现约560万美元。市场分析认为，此次减持更可能是获利了结及投资组合再平衡，并不代表ARK看空AMD的基本面。","market":"us","thumbnail":"https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOD","HOOY","HOOZ","FBYY","AMDW","DAMD","IONS","HOOW","CCUP","META","AMDG","METD","AMD","AMDL","HOOI","CRCG","HOYY","HOOG","CRCL","AMYY","HODU","ROKU","NTRA","AMDD","FBL","HOOX","ICRC","CRCO","METU","CRCD","AMDU","HOII","ROBN","AMUU","METW","AMDY","CRCA","FBY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1101026949","title":"异动解读｜Ionis Pharmaceuticals盘中下跌6.04%，核心管线三期试验失败余震延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1101026949","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101026949?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:37","pubTimestamp":1783690641,"startTime":"0","endTime":"0","summary":"7月10日，Ionis Pharmaceuticals盘中下跌6.04%，报59.59美元/股，成交额4121.97万美元，延续前一交易日超20%的暴跌走势。消息面上，Ionis与合作伙伴阿斯利康此前宣布，其药物Eplontersen针对转甲状腺素蛋白介导的淀粉样心肌病的三期临床试验Cardio-Ttransform未能达到主要疗效终点。ATTR-CM为Ionis心脏代谢管线核心适应症，此次失败构成重大挫折。此外，TD Cowen将Ionis目标价从108美元下调至94美元，维持买入评级，进一步压制市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118873423","title":"异动解读｜Ionis Pharmaceuticals盘中下跌20.03%，核心管线Eplontersen三期心脏试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1118873423","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118873423?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:46","pubTimestamp":1783608396,"startTime":"0","endTime":"0","summary":"7月9日，Ionis Pharmaceuticals盘中下跌20.03%，报67.55美元/股，成交额5.38亿美元。消息面上，Ionis与合作伙伴阿斯利康宣布，其药物Eplontersen针对转甲状腺素蛋白介导的淀粉样心肌病的三期临床试验Cardio-Ttransform未能达到主要疗效终点。ATTR-CM是Ionis心脏代谢管线的核心适应症之一，此次试验失败对公司该领域布局构成重大挫折。Ionis与阿斯利康计划继续分析完整数据，并将于8月欧洲心脏病学会大会上公布详细结果。受同一消息拖累，阿斯利康盘前亦跌超8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929828","title":"联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929828","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650929828?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:57","pubTimestamp":1783598269,"startTime":"0","endTime":"0","summary":"7月9日，阿斯利康与IONS联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465485.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443978.SGD","LU0289739699.SGD","BK4139","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU2462157665.USD","LU2456880835.USD","AZNH","LU2468319806.SGD","LU1267930573.SGD","LU2237443622.USD","LU0109394709.USD","LU2237443382.USD","LU1829250122.USD","LU2237443895.HKD","LU0128525929.USD","III","LU2236285917.USD","IONS","BK4588","LU2417539215.USD","BK4007","LU0310800379.SGD","BK4134","LU2237443465.HKD","LU2089984988.USD","LU2237443549.SGD","LU0708994859.HKD","LU0029864427.USD","IE00B3T34201.USD","BK4568","LU0432979614.USD","AZN","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650929827","title":"联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650929827?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:29","pubTimestamp":1783596558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443382.USD","LU2236285917.USD","LU0708994859.HKD","LU1829250122.USD","III","LU2468319806.SGD","LU0058720904.USD","AZN","LU0889565916.HKD","LU0128525929.USD","BK4588","LU2237443549.SGD","LU0310800379.SGD","AZNH","LU0289739699.SGD","LU0109394709.USD","LU2237443465.HKD","IONS","LU1267930573.SGD","BK4134","BK4568","LU0320765992.SGD","IE00B3T34201.USD","LU2089984988.USD","BK4007","LU2417539215.USD","LU2237443622.USD","BK4139","LU2237443978.SGD","LU0432979614.USD","LU2462157665.USD","BK4585","LU0029864427.USD","LU2456880835.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107257650","title":"与阿斯利康合作研发药物三期心脏病试验失败，Ionis Pharmaceuticals盘前股价大跌13.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107257650","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107257650?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:29","pubTimestamp":1783585755,"startTime":"0","endTime":"0","summary":"因与阿斯利康制药合作开发的一款药物在晚期心脏病临床试验中未能达到主要终点，Ionis Pharmaceuticals, Inc的股价在盘前交易时段应声下挫13.8%。此次试验挫折对市场关于该药物前景的预期造成了显著打击，导致投资者迅速抛售股票。股价的剧烈波动反映出市场对生物制药公司研发管线进展的高度敏感性，尤其是在关键后期试验阶段的结果公布之时。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211327993.USD","LU0499090636.EUR","LU0203345920.USD","LU0857590862.USD","LU2468319806.SGD","LU0708994859.HKD","LU0972486137.USD","LU0047473722.SGD","IE00BJT1NW94.SGD","LU0203347892.USD","LU0889566641.SGD","LU1061106388.HKD","LU0859254822.USD","LU0211326839.USD","LU2133065610.SGD","LU0784384876.USD","LU0047473722.EUR","LU0575583348.USD","LU1170363599.USD","SG9999001176.USD","LU0077335932.USD","LU1481600234.SGD","LU0963555726.SGD","LU0882574055.USD","LU2539964713.USD","LU0052756011.USD","LU1496350171.SGD","LU1923622614.USD","LU1989772923.USD","LU0496365809.HKD","LU0345777147.USD","LU1104425308.USD","LU0114720955.EUR","IE00BKPKM643.USD","LU2279689827.SGD","LU0640478417.SGD","LU0960981461.USD","LU2023251221.USD","SG9999013999.USD","LU1989771016.USD","LU2355687059.USD","LU0058720904.USD","LU0949170426.SGD","LU0029864427.USD","LU1291159041.SGD","LU1496350502.SGD","LU2237443465.HKD","LU0122379950.USD","LU1323610961.USD","LU0920840948.USD","LU1046234339.USD","LU2237443382.USD","LU0964806797.USD","LU0289739699.SGD","LU0557290698.USD","BK5011","LU1267930490.SGD","IE0034235188.USD","LU1355424745.HKD","LU1019632923.USD","BK4139","LU0128525929.USD","LU0128525689.USD","AZN.UK","IE00B3T34201.USD","LU2089984988.USD","LU2237443895.HKD","LU0545039389.USD","SG9999001176.SGD","LU0171293334.USD","LU2108987350.USD","LU1003076772.USD","LU1051770623.HKD","LU1487256676.USD","LU0997586515.USD","LU0310799852.SGD","IE0009355771.USD","LU0823399737.USD","LU0390134368.USD","LU0889565080.SGD","LU1196032939.SGD","LU1273509221.SGD","LU2293690249.USD","LU0757432116.USD","LU1267930813.SGD","LU2112291526.USD","LU1814569148.SGD","LU2125909593.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU2091194634.USD","LU0345777659.USD","LU0823416689.USD","LU1119994496.HKD","IE00B2B36J28.USD","LU1880407132.USD","LU2125909247.SGD","LU1153585028.USD","LU1880407215.USD","LU1015430645.USD","IE00BFTCPJ56.SGD","LU0969580561.USD","LU2089284900.SGD","LU1261432733.SGD","LU2293690082.USD","LU0553294199.USD","LU0211328371.USD","LU0784385840.USD","LU2357627491.SGD","LU0784385170.HKD","LU1019634622.SGD","IE00BJJMRZ35.SGD","LU0310800379.SGD","LU0997586432.USD","LU0432979614.USD","LU0266013472.USD","LU0310800965.SGD","LU1267930227.SGD","LU0211326755.USD","LU1829250122.USD","LU1078025761.USD","IONS","LU0526926950.USD","LU0011850046.USD","LU0887340254.USD","LU1267930573.SGD","LU2237443622.USD","LU2324357040.USD","LU0920783379.SGD","IE0002141913.USD","LU0738911758.USD","LU1153584641.USD","03165","SGXZ57979304.SGD","LU0784383803.USD","LU1064927863.SGD","LU0171276677.USD","LU2237443549.SGD","LU2237443978.SGD","LU1989772840.SGD","LU0661504455.SGD","LU0158827948.USD","LU1481599808.USD","LU0792757196.USD","LU0827474353.SGD","LU1057294990.SGD","LU0957799991.USD","LU0976567544.SGD","LU2089283258.USD","LU1983299246.USD","LU2114397693.USD","LU1301847155.USD","LU2433249047.HKD","LU0949170772.SGD","LU1084165304.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142104638","title":"异动解读｜Ionis Pharmaceuticals盘前下跌14.75%，核心管线三期试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1142104638","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142104638?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:20","pubTimestamp":1783585239,"startTime":"0","endTime":"0","summary":"7月9日，Ionis Pharmaceuticals盘前下跌14.75%，报74.68美元/股，成交额8.62万美元。消息面上，Ionis与合作伙伴阿斯利康宣布，其药物Eplontersen针对转甲状腺素蛋白介导的淀粉样心肌病的三期临床试验Cardio-Ttransform未能达到主要疗效终点。Ionis与阿斯利康计划继续分析完整数据，并于8月欧洲心脏病学会大会上公布结果。Ionis是一家商业阶段生物技术公司，拥有七种已上市药物，管线覆盖神经病学、心脏代谢疾病等领域，此次ATTR-CM试验失败对其心脏代谢管线构成重大挫折。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123213240","title":"Ionis制药Eplontersen三期心脏转归试验至第140周未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123213240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123213240?lang=zh_cn&edition=full","pubTime":"2026-07-09 14:02","pubTimestamp":1783576945,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc宣布，其针对药物Eplontersen开展的三期心脏转归临床试验“Cardio-Ttransform”，在截至第140周的分析中未能达到主要研究终点。\n该试验旨在评估Eplontersen在特定患者群体中的心血管获益。尽管未能达到预设的主要终点，但公司表示，试验过程中收集到的全面数据正在进行深入分析，以评估药物的整体获益风险特征，并为未来的开发决策提供依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138721848","title":"Eplontersen治疗转甲状腺素蛋白介导淀粉样心肌病成人患者的Cardio-Ttransform三期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1138721848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138721848?lang=zh_cn&edition=full","pubTime":"2026-07-09 14:00","pubTimestamp":1783576824,"startTime":"0","endTime":"0","summary":"针对Eplontersen用于治疗转甲状腺素蛋白介导的淀粉样心肌病成人患者的Cardio-Ttransform三期临床试验，现已发布最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165978696","title":"Ionis完成昂丹司琼治疗安格曼综合征三期Reveal研究关键队列入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1165978696","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165978696?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:03","pubTimestamp":1783335805,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals（纳斯达克股票代码：IONS）已成功完成其三期临床试验Reveal研究关键队列的患者入组工作，该研究旨在评估药物昂丹司琼（Obudanersen）用于治疗安格曼综合征的疗效。\n这项名为Reveal的研究是评估昂丹司琼的关键性试验，其核心队列的入组完成标志着该药物研发进程中的一个重要里程碑。安格曼综合征是一种罕见的神经遗传性疾病，目前治疗选择有限，因此该疗法的进展备受关注。\n公司表示，将按计划推进后续的临床试验和数据收集工作，以评估该药物的安全性和有效性。这一进展为潜在的新治疗方案带来了希望，也反映了Ionis在RNA靶向疗法领域的持续探索。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102650612","title":"异动解读｜Ionis制药盘中上涨5.32%，Zilganersen全球商业化布局加速落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1102650612","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102650612?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:30","pubTimestamp":1782484257,"startTime":"0","endTime":"0","summary":"消息面上，公司宣布将亚历山大病在研药物Zilganersen的美国以外全球权益授权给Recordati，获得3000万美元预付款及最高达中20%区间的年净销售额里程碑付款和特许权使用费，同时保留美国市场独立商业化权利。该药此前在关键性研究中达到主要终点，50mg剂量在5岁及以上患者中展现出具统计学意义的步速稳定效果，并获得FDA优先审评资格。此次授权协议标志着公司在罕见病领域的商业化路径进一步明确，美国独立上市叠加海外合作模式有望最大化药物商业价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137969890","title":"艾奥尼斯制药计划独立在美国推出Zilganersen；FDA设定PDUFA日期为9月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1137969890","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137969890?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:02","pubTimestamp":1782370975,"startTime":"0","endTime":"0","summary":"艾奥尼斯制药公司宣布，计划独立在美国市场推出其药物Zilganersen。与此同时，美国食品药品监督管理局已将该药物的处方药使用者付费法案目标审评日期设定在9月22日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178831274","title":"Ionis与Recordati就亚历山大病药物Zilganersen达成美国以外全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1178831274","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178831274?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:00","pubTimestamp":1782370818,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布与Recordati公司就治疗亚历山大病的在研药物Zilganersen达成授权协议，该协议覆盖美国以外的所有国家和地区。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195534514","title":"Tryngolza®（奥莱扎森）获FDA批准，成为首个且唯一用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1195534514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195534514?lang=zh_cn&edition=full","pubTime":"2026-06-25 02:37","pubTimestamp":1782326235,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Tryngolza®（奥莱扎森）上市，该药物成为首个且唯一获批用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196480472","title":"FDA批准首款可降低成人严重高甘油三酯血症患者急性胰腺炎风险的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1196480472","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196480472?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:36","pubTimestamp":1782318972,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准首款经证实能够降低患有严重高甘油三酯血症的成人患者发生急性胰腺炎风险的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionis.com","stockEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":0.0171},{"period":"3month","weight":-0.2473},{"period":"6month","weight":-0.3068},{"period":"1year","weight":0.2963},{"period":"ytd","weight":-0.2938}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司于1989年在加利福尼亚州注册成立，并于1991年1月将公司注册州变更为特拉华州。该公司花了三十年时间开拓RNA靶向药物，并已发展成为一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，并拥有横跨神经病学、心脏代谢疾病和其他患者高需求领域的强大管道。它继续通过独立和合作开发推进下一代RNA靶向技术，为患有严重疾病的患者提供创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.015383},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.032273},{"month":4,"riseRate":0.363636,"avgChangeRate":0.01605},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.042937},{"month":6,"riseRate":0.818182,"avgChangeRate":0.057374},{"month":7,"riseRate":0.727273,"avgChangeRate":0.00605},{"month":8,"riseRate":0.545455,"avgChangeRate":0.018313},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}